(Reuters) -Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, as the drugmaker seeks to boost its U.S. manufacturing in the face of President Donald Trump's ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...

Exclusive-Merck Vaccine Case Linked to HHS Secretary Kennedy Delayed Mid-Trial By Dan Levine and Mike Spector (Reuters) - Merck and a woman suing the drugmaker agreed to halt a trial over alleged ...

Merck, a global leader in science and technology, showcased artificial intelligence (AI) driven materials solutions and digitalization capabilities through its materials intelligence platform at ...

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Merck & Co... We recently published a list of the 11 Best Pharma Stocks to Buy According ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...